ArticleDiscover oncology2026
Hypofractionated radiotherapy for prostate cancer: a bibliometric analysis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This comprehensive bibliometric analysis of 1,428 publications from the WoSCC reveals the rapid expansion and maturation of research on hypofractionated radiotherapy (HFRT) for prostate cancer, characterized by an average annual growth rate of 13.28% since 2020. Led by prominent contributions from the United States, Italy, and the University of Toronto, the field has evolved from foundational radiobiological concepts and early conformal techniques toward current research hotspots focused on high-precision delivery, such as image-guided radiotherapy (IGRT) and stereotactic body radiation therapy (SBRT), as well as robust clinical validation through randomized non-inferiority trials. The findings highlight a multidisciplinary ecosystem that increasingly integrates technological advancements with quality-of-life assessments. Moving forward, the research trajectory is expected to prioritize personalized adaptive radiotherapy, biomarker integration, and the resolution of practical implementation challenges to further refine and enhance clinical outcomes for prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.